nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—CYP3A4—Temozolomide—melanoma	0.0733	0.576	CbGbCtD
Levonorgestrel—CYP3A4—Vemurafenib—melanoma	0.0402	0.316	CbGbCtD
Levonorgestrel—CYP3A4—Docetaxel—melanoma	0.0138	0.108	CbGbCtD
Levonorgestrel—SHBG—hindlimb—melanoma	0.00771	0.221	CbGeAlD
Levonorgestrel—SRD5A1—eye—melanoma	0.00538	0.155	CbGeAlD
Levonorgestrel—PGR—blood vessel—melanoma	0.00331	0.0953	CbGeAlD
Levonorgestrel—SRD5A1—head—melanoma	0.00305	0.0877	CbGeAlD
Levonorgestrel—Testosterone Propionate—CYP17A1—melanoma	0.00274	0.323	CrCbGaD
Levonorgestrel—SHBG—neck—melanoma	0.00263	0.0756	CbGeAlD
Levonorgestrel—ESR1—blood vessel—melanoma	0.00259	0.0745	CbGeAlD
Levonorgestrel—ESR1—neck—melanoma	0.00185	0.0533	CbGeAlD
Levonorgestrel—Fluid retention—Docetaxel—melanoma	0.00153	0.00356	CcSEcCtD
Levonorgestrel—Pneumonia—Dactinomycin—melanoma	0.00151	0.00351	CcSEcCtD
Levonorgestrel—Sweating increased—Temozolomide—melanoma	0.00148	0.00345	CcSEcCtD
Levonorgestrel—Decreased appetite—Vemurafenib—melanoma	0.00147	0.00343	CcSEcCtD
Levonorgestrel—Bronchitis—Temozolomide—melanoma	0.00146	0.00341	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Vemurafenib—melanoma	0.00146	0.0034	CcSEcCtD
Levonorgestrel—Fatigue—Vemurafenib—melanoma	0.00146	0.0034	CcSEcCtD
Levonorgestrel—Neoplasm—Docetaxel—melanoma	0.00146	0.00339	CcSEcCtD
Levonorgestrel—Haemoglobin—Bleomycin—melanoma	0.00145	0.00338	CcSEcCtD
Levonorgestrel—Constipation—Vemurafenib—melanoma	0.00145	0.00337	CcSEcCtD
Levonorgestrel—Haemorrhage—Bleomycin—melanoma	0.00144	0.00336	CcSEcCtD
Levonorgestrel—Lightheadedness—Docetaxel—melanoma	0.00144	0.00336	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Bleomycin—melanoma	0.00144	0.00334	CcSEcCtD
Levonorgestrel—Dysuria—Temozolomide—melanoma	0.00142	0.00331	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Temozolomide—melanoma	0.00141	0.00329	CcSEcCtD
Levonorgestrel—Pneumonia—Carmustine—melanoma	0.00141	0.00329	CcSEcCtD
Levonorgestrel—Pollakiuria—Temozolomide—melanoma	0.00141	0.00327	CcSEcCtD
Levonorgestrel—Depression—Carmustine—melanoma	0.0014	0.00326	CcSEcCtD
Levonorgestrel—Weight increased—Temozolomide—melanoma	0.00139	0.00322	CcSEcCtD
Levonorgestrel—Weight decreased—Temozolomide—melanoma	0.00138	0.0032	CcSEcCtD
Levonorgestrel—Urinary tract infection—Carmustine—melanoma	0.00137	0.00318	CcSEcCtD
Levonorgestrel—Pneumonia—Temozolomide—melanoma	0.00137	0.00318	CcSEcCtD
Levonorgestrel—Infestation—Temozolomide—melanoma	0.00136	0.00316	CcSEcCtD
Levonorgestrel—Infestation NOS—Temozolomide—melanoma	0.00136	0.00316	CcSEcCtD
Levonorgestrel—Depression—Temozolomide—melanoma	0.00135	0.00315	CcSEcCtD
Levonorgestrel—Body temperature increased—Vemurafenib—melanoma	0.00134	0.00311	CcSEcCtD
Levonorgestrel—Pharyngitis—Dactinomycin—melanoma	0.00134	0.00311	CcSEcCtD
Levonorgestrel—Urinary tract infection—Temozolomide—melanoma	0.00132	0.00307	CcSEcCtD
Levonorgestrel—Alopecia—Bleomycin—melanoma	0.00128	0.00297	CcSEcCtD
Levonorgestrel—Erythema multiforme—Dactinomycin—melanoma	0.00127	0.00296	CcSEcCtD
Levonorgestrel—Sinusitis—Temozolomide—melanoma	0.00127	0.00296	CcSEcCtD
Levonorgestrel—Haemoglobin—Carmustine—melanoma	0.00127	0.00295	CcSEcCtD
Levonorgestrel—Haemorrhage—Carmustine—melanoma	0.00126	0.00293	CcSEcCtD
Levonorgestrel—Progesterone—CYP17A1—melanoma	0.00126	0.148	CrCbGaD
Levonorgestrel—Erythema—Bleomycin—melanoma	0.00126	0.00292	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Carmustine—melanoma	0.00125	0.00292	CcSEcCtD
Levonorgestrel—Hypersensitivity—Vemurafenib—melanoma	0.00125	0.0029	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Carmustine—melanoma	0.00124	0.00288	CcSEcCtD
Levonorgestrel—Haemoglobin—Temozolomide—melanoma	0.00122	0.00285	CcSEcCtD
Levonorgestrel—AR—skin of body—melanoma	0.00122	0.0351	CbGeAlD
Levonorgestrel—Haemorrhage—Temozolomide—melanoma	0.00122	0.00283	CcSEcCtD
Levonorgestrel—Asthenia—Vemurafenib—melanoma	0.00122	0.00283	CcSEcCtD
Levonorgestrel—Visual impairment—Carmustine—melanoma	0.00122	0.00283	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Temozolomide—melanoma	0.00121	0.00282	CcSEcCtD
Levonorgestrel—Pharyngitis—Temozolomide—melanoma	0.00121	0.00281	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Temozolomide—melanoma	0.0012	0.0028	CcSEcCtD
Levonorgestrel—Pruritus—Vemurafenib—melanoma	0.0012	0.00279	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Temozolomide—melanoma	0.0012	0.00279	CcSEcCtD
Levonorgestrel—Urethral disorder—Temozolomide—melanoma	0.00119	0.00278	CcSEcCtD
Levonorgestrel—Alopecia—Dactinomycin—melanoma	0.00119	0.00277	CcSEcCtD
Levonorgestrel—Eye disorder—Carmustine—melanoma	0.00118	0.00274	CcSEcCtD
Levonorgestrel—Visual impairment—Temozolomide—melanoma	0.00117	0.00273	CcSEcCtD
Levonorgestrel—Erythema—Dactinomycin—melanoma	0.00117	0.00273	CcSEcCtD
Levonorgestrel—Pain in extremity—Docetaxel—melanoma	0.00117	0.00272	CcSEcCtD
Levonorgestrel—Anaemia—Bleomycin—melanoma	0.00116	0.0027	CcSEcCtD
Levonorgestrel—Diarrhoea—Vemurafenib—melanoma	0.00116	0.0027	CcSEcCtD
Levonorgestrel—Migraine—Docetaxel—melanoma	0.00115	0.00268	CcSEcCtD
Levonorgestrel—Erythema multiforme—Temozolomide—melanoma	0.00115	0.00268	CcSEcCtD
Levonorgestrel—Eye disorder—Temozolomide—melanoma	0.00114	0.00265	CcSEcCtD
Levonorgestrel—Cardiac disorder—Temozolomide—melanoma	0.00113	0.00263	CcSEcCtD
Levonorgestrel—Arrhythmia—Carmustine—melanoma	0.00113	0.00262	CcSEcCtD
Levonorgestrel—Dizziness—Vemurafenib—melanoma	0.00112	0.00261	CcSEcCtD
Levonorgestrel—AR—mammalian vulva—melanoma	0.00112	0.032	CbGeAlD
Levonorgestrel—Alopecia—Carmustine—melanoma	0.00111	0.00259	CcSEcCtD
Levonorgestrel—Mental disorder—Carmustine—melanoma	0.0011	0.00257	CcSEcCtD
Levonorgestrel—Immune system disorder—Temozolomide—melanoma	0.0011	0.00256	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Temozolomide—melanoma	0.0011	0.00255	CcSEcCtD
Levonorgestrel—Malnutrition—Carmustine—melanoma	0.0011	0.00255	CcSEcCtD
Levonorgestrel—Erythema—Carmustine—melanoma	0.0011	0.00255	CcSEcCtD
Levonorgestrel—Cough—Bleomycin—melanoma	0.0011	0.00255	CcSEcCtD
Levonorgestrel—Anaemia—Dactinomycin—melanoma	0.00108	0.00252	CcSEcCtD
Levonorgestrel—Vomiting—Vemurafenib—melanoma	0.00108	0.00251	CcSEcCtD
Levonorgestrel—Alopecia—Temozolomide—melanoma	0.00108	0.0025	CcSEcCtD
Levonorgestrel—Dry skin—Docetaxel—melanoma	0.00107	0.0025	CcSEcCtD
Levonorgestrel—Myalgia—Bleomycin—melanoma	0.00107	0.00249	CcSEcCtD
Levonorgestrel—Chest pain—Bleomycin—melanoma	0.00107	0.00249	CcSEcCtD
Levonorgestrel—Rash—Vemurafenib—melanoma	0.00107	0.00248	CcSEcCtD
Levonorgestrel—Mental disorder—Temozolomide—melanoma	0.00107	0.00248	CcSEcCtD
Levonorgestrel—Dermatitis—Vemurafenib—melanoma	0.00107	0.00248	CcSEcCtD
Levonorgestrel—Back pain—Carmustine—melanoma	0.00106	0.00247	CcSEcCtD
Levonorgestrel—Headache—Vemurafenib—melanoma	0.00106	0.00247	CcSEcCtD
Levonorgestrel—Malnutrition—Temozolomide—melanoma	0.00106	0.00247	CcSEcCtD
Levonorgestrel—Erythema—Temozolomide—melanoma	0.00106	0.00247	CcSEcCtD
Levonorgestrel—Breast disorder—Docetaxel—melanoma	0.00106	0.00246	CcSEcCtD
Levonorgestrel—Discomfort—Bleomycin—melanoma	0.00106	0.00246	CcSEcCtD
Levonorgestrel—Oedema—Bleomycin—melanoma	0.00103	0.00239	CcSEcCtD
Levonorgestrel—Back pain—Temozolomide—melanoma	0.00103	0.00239	CcSEcCtD
Levonorgestrel—Infection—Bleomycin—melanoma	0.00102	0.00237	CcSEcCtD
Levonorgestrel—Anaemia—Carmustine—melanoma	0.00101	0.00236	CcSEcCtD
Levonorgestrel—Nausea—Vemurafenib—melanoma	0.00101	0.00234	CcSEcCtD
Levonorgestrel—PGR—head—melanoma	0.001	0.0288	CbGeAlD
Levonorgestrel—Myalgia—Dactinomycin—melanoma	0.000999	0.00232	CcSEcCtD
Levonorgestrel—Discomfort—Dactinomycin—melanoma	0.000987	0.00229	CcSEcCtD
Levonorgestrel—Anaemia—Temozolomide—melanoma	0.00098	0.00228	CcSEcCtD
Levonorgestrel—Anorexia—Bleomycin—melanoma	0.000978	0.00228	CcSEcCtD
Levonorgestrel—Angioedema—Temozolomide—melanoma	0.000969	0.00225	CcSEcCtD
Levonorgestrel—Oedema—Dactinomycin—melanoma	0.000957	0.00223	CcSEcCtD
Levonorgestrel—Vertigo—Temozolomide—melanoma	0.000953	0.00222	CcSEcCtD
Levonorgestrel—Infection—Dactinomycin—melanoma	0.000951	0.00221	CcSEcCtD
Levonorgestrel—Hypertension—Carmustine—melanoma	0.000948	0.0022	CcSEcCtD
Levonorgestrel—Palpitations—Temozolomide—melanoma	0.000937	0.00218	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Bleomycin—melanoma	0.000935	0.00217	CcSEcCtD
Levonorgestrel—Chest pain—Carmustine—melanoma	0.000935	0.00217	CcSEcCtD
Levonorgestrel—Myalgia—Carmustine—melanoma	0.000935	0.00217	CcSEcCtD
Levonorgestrel—Anxiety—Carmustine—melanoma	0.000931	0.00217	CcSEcCtD
Levonorgestrel—Cough—Temozolomide—melanoma	0.000926	0.00215	CcSEcCtD
Levonorgestrel—Weight increased—Docetaxel—melanoma	0.000921	0.00214	CcSEcCtD
Levonorgestrel—Weight decreased—Docetaxel—melanoma	0.000916	0.00213	CcSEcCtD
Levonorgestrel—Hypertension—Temozolomide—melanoma	0.000916	0.00213	CcSEcCtD
Levonorgestrel—Dyspnoea—Bleomycin—melanoma	0.000915	0.00213	CcSEcCtD
Levonorgestrel—Anorexia—Dactinomycin—melanoma	0.000912	0.00212	CcSEcCtD
Levonorgestrel—Pneumonia—Docetaxel—melanoma	0.000908	0.00211	CcSEcCtD
Levonorgestrel—Myalgia—Temozolomide—melanoma	0.000903	0.0021	CcSEcCtD
Levonorgestrel—Infestation—Docetaxel—melanoma	0.000903	0.0021	CcSEcCtD
Levonorgestrel—Infestation NOS—Docetaxel—melanoma	0.000903	0.0021	CcSEcCtD
Levonorgestrel—CYP19A1—head—melanoma	0.000901	0.0259	CbGeAlD
Levonorgestrel—Anxiety—Temozolomide—melanoma	0.0009	0.00209	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000897	0.00209	CcSEcCtD
Levonorgestrel—Oedema—Carmustine—melanoma	0.000896	0.00208	CcSEcCtD
Levonorgestrel—Discomfort—Temozolomide—melanoma	0.000892	0.00208	CcSEcCtD
Levonorgestrel—Decreased appetite—Bleomycin—melanoma	0.000892	0.00208	CcSEcCtD
Levonorgestrel—Infection—Carmustine—melanoma	0.00089	0.00207	CcSEcCtD
Levonorgestrel—Pain—Bleomycin—melanoma	0.000878	0.00204	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000872	0.00203	CcSEcCtD
Levonorgestrel—Progesterone—CYP1B1—melanoma	0.000872	0.103	CrCbGaD
Levonorgestrel—Oedema—Temozolomide—melanoma	0.000866	0.00201	CcSEcCtD
Levonorgestrel—Infection—Temozolomide—melanoma	0.00086	0.002	CcSEcCtD
Levonorgestrel—Anorexia—Carmustine—melanoma	0.000854	0.00199	CcSEcCtD
Levonorgestrel—Nervous system disorder—Temozolomide—melanoma	0.000849	0.00197	CcSEcCtD
Levonorgestrel—Skin disorder—Temozolomide—melanoma	0.000841	0.00196	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Temozolomide—melanoma	0.000837	0.00195	CcSEcCtD
Levonorgestrel—Decreased appetite—Dactinomycin—melanoma	0.000832	0.00194	CcSEcCtD
Levonorgestrel—Fatigue—Dactinomycin—melanoma	0.000825	0.00192	CcSEcCtD
Levonorgestrel—Anorexia—Temozolomide—melanoma	0.000825	0.00192	CcSEcCtD
Levonorgestrel—Testosterone—CYP1B1—melanoma	0.000824	0.0971	CrCbGaD
Levonorgestrel—Pain—Dactinomycin—melanoma	0.000819	0.0019	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Carmustine—melanoma	0.000816	0.0019	CcSEcCtD
Levonorgestrel—Urticaria—Bleomycin—melanoma	0.000815	0.0019	CcSEcCtD
Levonorgestrel—Haemoglobin—Docetaxel—melanoma	0.000815	0.00189	CcSEcCtD
Levonorgestrel—Rhinitis—Docetaxel—melanoma	0.000812	0.00189	CcSEcCtD
Levonorgestrel—Body temperature increased—Bleomycin—melanoma	0.000811	0.00189	CcSEcCtD
Levonorgestrel—Haemorrhage—Docetaxel—melanoma	0.00081	0.00188	CcSEcCtD
Levonorgestrel—Insomnia—Carmustine—melanoma	0.00081	0.00188	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Docetaxel—melanoma	0.000806	0.00188	CcSEcCtD
Levonorgestrel—Pharyngitis—Docetaxel—melanoma	0.000804	0.00187	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Docetaxel—melanoma	0.0008	0.00186	CcSEcCtD
Levonorgestrel—Dyspnoea—Carmustine—melanoma	0.000799	0.00186	CcSEcCtD
Levonorgestrel—AR—head—melanoma	0.000798	0.0229	CbGeAlD
Levonorgestrel—Somnolence—Carmustine—melanoma	0.000796	0.00185	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Docetaxel—melanoma	0.000796	0.00185	CcSEcCtD
Levonorgestrel—Urethral disorder—Docetaxel—melanoma	0.000794	0.00185	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Temozolomide—melanoma	0.000789	0.00183	CcSEcCtD
Levonorgestrel—ESR1—head—melanoma	0.000783	0.0225	CbGeAlD
Levonorgestrel—Insomnia—Temozolomide—melanoma	0.000783	0.00182	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Dactinomycin—melanoma	0.000783	0.00182	CcSEcCtD
Levonorgestrel—Visual impairment—Docetaxel—melanoma	0.000781	0.00182	CcSEcCtD
Levonorgestrel—Decreased appetite—Carmustine—melanoma	0.000779	0.00181	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Carmustine—melanoma	0.000773	0.0018	CcSEcCtD
Levonorgestrel—Dyspnoea—Temozolomide—melanoma	0.000772	0.0018	CcSEcCtD
Levonorgestrel—Somnolence—Temozolomide—melanoma	0.00077	0.00179	CcSEcCtD
Levonorgestrel—Erythema multiforme—Docetaxel—melanoma	0.000766	0.00178	CcSEcCtD
Levonorgestrel—Constipation—Carmustine—melanoma	0.000766	0.00178	CcSEcCtD
Levonorgestrel—Pain—Carmustine—melanoma	0.000766	0.00178	CcSEcCtD
Levonorgestrel—Dyspepsia—Temozolomide—melanoma	0.000762	0.00177	CcSEcCtD
Levonorgestrel—Eye disorder—Docetaxel—melanoma	0.000757	0.00176	CcSEcCtD
Levonorgestrel—Body temperature increased—Dactinomycin—melanoma	0.000757	0.00176	CcSEcCtD
Levonorgestrel—Abdominal pain—Dactinomycin—melanoma	0.000757	0.00176	CcSEcCtD
Levonorgestrel—Hypersensitivity—Bleomycin—melanoma	0.000756	0.00176	CcSEcCtD
Levonorgestrel—Decreased appetite—Temozolomide—melanoma	0.000753	0.00175	CcSEcCtD
Levonorgestrel—Cardiac disorder—Docetaxel—melanoma	0.000752	0.00175	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Temozolomide—melanoma	0.000747	0.00174	CcSEcCtD
Levonorgestrel—Fatigue—Temozolomide—melanoma	0.000746	0.00174	CcSEcCtD
Levonorgestrel—Pain—Temozolomide—melanoma	0.00074	0.00172	CcSEcCtD
Levonorgestrel—Constipation—Temozolomide—melanoma	0.00074	0.00172	CcSEcCtD
Levonorgestrel—Asthenia—Bleomycin—melanoma	0.000736	0.00171	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Carmustine—melanoma	0.000733	0.0017	CcSEcCtD
Levonorgestrel—Immune system disorder—Docetaxel—melanoma	0.000732	0.0017	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Docetaxel—melanoma	0.00073	0.0017	CcSEcCtD
Levonorgestrel—Pruritus—Bleomycin—melanoma	0.000726	0.00169	CcSEcCtD
Levonorgestrel—Arrhythmia—Docetaxel—melanoma	0.000724	0.00168	CcSEcCtD
Levonorgestrel—Alopecia—Docetaxel—melanoma	0.000716	0.00167	CcSEcCtD
Levonorgestrel—Mental disorder—Docetaxel—melanoma	0.00071	0.00165	CcSEcCtD
Levonorgestrel—Body temperature increased—Carmustine—melanoma	0.000708	0.00165	CcSEcCtD
Levonorgestrel—Abdominal pain—Carmustine—melanoma	0.000708	0.00165	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Temozolomide—melanoma	0.000708	0.00165	CcSEcCtD
Levonorgestrel—Malnutrition—Docetaxel—melanoma	0.000705	0.00164	CcSEcCtD
Levonorgestrel—Erythema—Docetaxel—melanoma	0.000705	0.00164	CcSEcCtD
Levonorgestrel—Hypersensitivity—Dactinomycin—melanoma	0.000705	0.00164	CcSEcCtD
Levonorgestrel—PGR—lymph node—melanoma	0.000701	0.0202	CbGeAlD
Levonorgestrel—Urticaria—Temozolomide—melanoma	0.000688	0.0016	CcSEcCtD
Levonorgestrel—Asthenia—Dactinomycin—melanoma	0.000687	0.0016	CcSEcCtD
Levonorgestrel—Abdominal pain—Temozolomide—melanoma	0.000684	0.00159	CcSEcCtD
Levonorgestrel—Body temperature increased—Temozolomide—melanoma	0.000684	0.00159	CcSEcCtD
Levonorgestrel—Back pain—Docetaxel—melanoma	0.000682	0.00159	CcSEcCtD
Levonorgestrel—Muscle spasms—Docetaxel—melanoma	0.000678	0.00158	CcSEcCtD
Levonorgestrel—Hypersensitivity—Carmustine—melanoma	0.00066	0.00154	CcSEcCtD
Levonorgestrel—Diarrhoea—Dactinomycin—melanoma	0.000655	0.00152	CcSEcCtD
Levonorgestrel—Vomiting—Bleomycin—melanoma	0.000653	0.00152	CcSEcCtD
Levonorgestrel—Anaemia—Docetaxel—melanoma	0.000652	0.00152	CcSEcCtD
Levonorgestrel—Rash—Bleomycin—melanoma	0.000647	0.00151	CcSEcCtD
Levonorgestrel—Dermatitis—Bleomycin—melanoma	0.000647	0.0015	CcSEcCtD
Levonorgestrel—Asthenia—Carmustine—melanoma	0.000643	0.0015	CcSEcCtD
Levonorgestrel—Hypersensitivity—Temozolomide—melanoma	0.000638	0.00148	CcSEcCtD
Levonorgestrel—Syncope—Docetaxel—melanoma	0.000633	0.00147	CcSEcCtD
Levonorgestrel—CYP19A1—lymph node—melanoma	0.000631	0.0181	CbGeAlD
Levonorgestrel—Palpitations—Docetaxel—melanoma	0.000623	0.00145	CcSEcCtD
Levonorgestrel—Asthenia—Temozolomide—melanoma	0.000621	0.00144	CcSEcCtD
Levonorgestrel—Loss of consciousness—Docetaxel—melanoma	0.00062	0.00144	CcSEcCtD
Levonorgestrel—Cough—Docetaxel—melanoma	0.000616	0.00143	CcSEcCtD
Levonorgestrel—Diarrhoea—Carmustine—melanoma	0.000613	0.00143	CcSEcCtD
Levonorgestrel—Pruritus—Temozolomide—melanoma	0.000613	0.00142	CcSEcCtD
Levonorgestrel—Nausea—Bleomycin—melanoma	0.00061	0.00142	CcSEcCtD
Levonorgestrel—Hypertension—Docetaxel—melanoma	0.000609	0.00142	CcSEcCtD
Levonorgestrel—Vomiting—Dactinomycin—melanoma	0.000609	0.00142	CcSEcCtD
Levonorgestrel—Rash—Dactinomycin—melanoma	0.000604	0.0014	CcSEcCtD
Levonorgestrel—Chest pain—Docetaxel—melanoma	0.000601	0.0014	CcSEcCtD
Levonorgestrel—Myalgia—Docetaxel—melanoma	0.000601	0.0014	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000596	0.00139	CcSEcCtD
Levonorgestrel—Dizziness—Carmustine—melanoma	0.000592	0.00138	CcSEcCtD
Levonorgestrel—Diarrhoea—Temozolomide—melanoma	0.000592	0.00138	CcSEcCtD
Levonorgestrel—Oedema—Docetaxel—melanoma	0.000576	0.00134	CcSEcCtD
Levonorgestrel—Dizziness—Temozolomide—melanoma	0.000573	0.00133	CcSEcCtD
Levonorgestrel—Infection—Docetaxel—melanoma	0.000572	0.00133	CcSEcCtD
Levonorgestrel—Vomiting—Carmustine—melanoma	0.00057	0.00132	CcSEcCtD
Levonorgestrel—Nausea—Dactinomycin—melanoma	0.000569	0.00132	CcSEcCtD
Levonorgestrel—Shock—Docetaxel—melanoma	0.000566	0.00132	CcSEcCtD
Levonorgestrel—Rash—Carmustine—melanoma	0.000565	0.00131	CcSEcCtD
Levonorgestrel—Nervous system disorder—Docetaxel—melanoma	0.000565	0.00131	CcSEcCtD
Levonorgestrel—Dermatitis—Carmustine—melanoma	0.000564	0.00131	CcSEcCtD
Levonorgestrel—Headache—Carmustine—melanoma	0.000561	0.00131	CcSEcCtD
Levonorgestrel—Skin disorder—Docetaxel—melanoma	0.000559	0.0013	CcSEcCtD
Levonorgestrel—AR—lymph node—melanoma	0.000559	0.0161	CbGeAlD
Levonorgestrel—Vomiting—Temozolomide—melanoma	0.00055	0.00128	CcSEcCtD
Levonorgestrel—Anorexia—Docetaxel—melanoma	0.000549	0.00128	CcSEcCtD
Levonorgestrel—ESR1—lymph node—melanoma	0.000548	0.0158	CbGeAlD
Levonorgestrel—Rash—Temozolomide—melanoma	0.000546	0.00127	CcSEcCtD
Levonorgestrel—Dermatitis—Temozolomide—melanoma	0.000545	0.00127	CcSEcCtD
Levonorgestrel—Headache—Temozolomide—melanoma	0.000542	0.00126	CcSEcCtD
Levonorgestrel—Nausea—Carmustine—melanoma	0.000532	0.00124	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Docetaxel—melanoma	0.000525	0.00122	CcSEcCtD
Levonorgestrel—Insomnia—Docetaxel—melanoma	0.000521	0.00121	CcSEcCtD
Levonorgestrel—Nausea—Temozolomide—melanoma	0.000514	0.0012	CcSEcCtD
Levonorgestrel—Dyspnoea—Docetaxel—melanoma	0.000513	0.00119	CcSEcCtD
Levonorgestrel—Somnolence—Docetaxel—melanoma	0.000512	0.00119	CcSEcCtD
Levonorgestrel—Dyspepsia—Docetaxel—melanoma	0.000507	0.00118	CcSEcCtD
Levonorgestrel—Decreased appetite—Docetaxel—melanoma	0.0005	0.00116	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Docetaxel—melanoma	0.000497	0.00116	CcSEcCtD
Levonorgestrel—Fatigue—Docetaxel—melanoma	0.000496	0.00115	CcSEcCtD
Levonorgestrel—Constipation—Docetaxel—melanoma	0.000492	0.00115	CcSEcCtD
Levonorgestrel—Pain—Docetaxel—melanoma	0.000492	0.00115	CcSEcCtD
Levonorgestrel—Gastrointestinal pain—Docetaxel—melanoma	0.000471	0.0011	CcSEcCtD
Levonorgestrel—Abdominal pain—Docetaxel—melanoma	0.000455	0.00106	CcSEcCtD
Levonorgestrel—Body temperature increased—Docetaxel—melanoma	0.000455	0.00106	CcSEcCtD
Levonorgestrel—Norethindrone—ALB—melanoma	0.00045	0.053	CrCbGaD
Levonorgestrel—Ethinyl Estradiol—ABCB1—melanoma	0.000446	0.0526	CrCbGaD
Levonorgestrel—Norethindrone—ABCB1—melanoma	0.000429	0.0506	CrCbGaD
Levonorgestrel—Methyltestosterone—ALB—melanoma	0.000427	0.0503	CrCbGaD
Levonorgestrel—Hypersensitivity—Docetaxel—melanoma	0.000424	0.000987	CcSEcCtD
Levonorgestrel—Asthenia—Docetaxel—melanoma	0.000413	0.000961	CcSEcCtD
Levonorgestrel—Pruritus—Docetaxel—melanoma	0.000407	0.000947	CcSEcCtD
Levonorgestrel—Diarrhoea—Docetaxel—melanoma	0.000394	0.000916	CcSEcCtD
Levonorgestrel—Dizziness—Docetaxel—melanoma	0.000381	0.000886	CcSEcCtD
Levonorgestrel—Vomiting—Docetaxel—melanoma	0.000366	0.000851	CcSEcCtD
Levonorgestrel—Rash—Docetaxel—melanoma	0.000363	0.000844	CcSEcCtD
Levonorgestrel—Dermatitis—Docetaxel—melanoma	0.000363	0.000844	CcSEcCtD
Levonorgestrel—Headache—Docetaxel—melanoma	0.000361	0.000839	CcSEcCtD
Levonorgestrel—Nausea—Docetaxel—melanoma	0.000342	0.000795	CcSEcCtD
Levonorgestrel—Hydrocortisone—ABCB1—melanoma	0.000307	0.0362	CrCbGaD
Levonorgestrel—Progesterone—ABCB1—melanoma	0.00025	0.0295	CrCbGaD
Levonorgestrel—Testosterone—ALB—melanoma	0.000248	0.0292	CrCbGaD
Levonorgestrel—Testosterone—ABCB1—melanoma	0.000237	0.0279	CrCbGaD
Levonorgestrel—ESR1—Signaling Pathways—KISS1—melanoma	9.45e-05	0.000237	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FLT1—melanoma	9.45e-05	0.000237	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—IL6—melanoma	9.41e-05	0.000236	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	9.39e-05	0.000235	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—VCAN—melanoma	9.34e-05	0.000234	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SKI—melanoma	9.16e-05	0.000229	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCR1—melanoma	9.16e-05	0.000229	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—PPARG—melanoma	9.09e-05	0.000227	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MC1R—melanoma	9.02e-05	0.000226	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCR4—melanoma	8.93e-05	0.000223	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HDAC2—melanoma	8.93e-05	0.000223	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FOXO4—melanoma	8.93e-05	0.000223	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	8.85e-05	0.000222	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8.84e-05	0.000221	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—MYC—melanoma	8.83e-05	0.000221	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—GNAQ—melanoma	8.83e-05	0.000221	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—melanoma	8.73e-05	0.000219	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—AKT1—melanoma	8.68e-05	0.000217	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GRM1—melanoma	8.65e-05	0.000216	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCR7—melanoma	8.65e-05	0.000216	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	8.57e-05	0.000214	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—melanoma	8.53e-05	0.000214	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PIK3CA—melanoma	8.47e-05	0.000212	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SUFU—melanoma	8.43e-05	0.000211	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—CDKN2B—melanoma	8.36e-05	0.000209	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SYK—melanoma	8.3e-05	0.000208	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—VDR—melanoma	8.15e-05	0.000204	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NGFR—melanoma	8.14e-05	0.000204	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ITGAV—melanoma	8.14e-05	0.000204	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT3—melanoma	8.14e-05	0.000204	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—HDAC2—melanoma	8.06e-05	0.000202	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—NOTCH1—melanoma	7.9e-05	0.000198	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP17A1—melanoma	7.88e-05	0.000197	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RHOB—melanoma	7.87e-05	0.000197	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BCL2L11—melanoma	7.87e-05	0.000197	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.77e-05	0.000195	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—ALB—melanoma	7.67e-05	0.000192	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HDAC6—melanoma	7.56e-05	0.000189	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ACER3—melanoma	7.55e-05	0.000189	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SOCS1—melanoma	7.54e-05	0.000189	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—S100B—melanoma	7.52e-05	0.000188	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PRKCA—melanoma	7.51e-05	0.000188	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PPARG—melanoma	7.46e-05	0.000187	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—ERCC2—melanoma	7.45e-05	0.000187	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GNA11—melanoma	7.44e-05	0.000186	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—FASN—melanoma	7.28e-05	0.000182	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	7.23e-05	0.000181	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB4—melanoma	7.19e-05	0.00018	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SLC5A5—melanoma	7.16e-05	0.000179	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCR2—melanoma	7.16e-05	0.000179	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN2B—melanoma	7.13e-05	0.000178	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RAC2—melanoma	7.05e-05	0.000176	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFC—melanoma	6.94e-05	0.000174	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—WNT5A—melanoma	6.94e-05	0.000174	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AKT1—melanoma	6.92e-05	0.000173	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—GNAQ—melanoma	6.92e-05	0.000173	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CD44—melanoma	6.92e-05	0.000173	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—UGT2B10—melanoma	6.9e-05	0.000173	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CD86—melanoma	6.9e-05	0.000173	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EDN1—melanoma	6.84e-05	0.000171	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.78e-05	0.00017	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MYC—melanoma	6.73e-05	0.000168	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.71e-05	0.000168	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGF1—melanoma	6.69e-05	0.000167	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CSF2—melanoma	6.69e-05	0.000167	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—CYP1B1—melanoma	6.63e-05	0.000166	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—E2F1—melanoma	6.55e-05	0.000164	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PDGFRA—melanoma	6.48e-05	0.000162	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—CDKN2B—melanoma	6.44e-05	0.000161	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HS3ST5—melanoma	6.42e-05	0.000161	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PRKCA—melanoma	6.41e-05	0.00016	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ITGB3—melanoma	6.41e-05	0.00016	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SPP1—melanoma	6.29e-05	0.000157	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—VDR—melanoma	6.28e-05	0.000157	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAP2K2—melanoma	6.27e-05	0.000157	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—F2R—melanoma	6.09e-05	0.000152	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—NOTCH1—melanoma	6.02e-05	0.000151	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TERT—melanoma	5.96e-05	0.000149	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—RAC1—melanoma	5.94e-05	0.000149	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EDNRB—melanoma	5.9e-05	0.000148	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.85e-05	0.000147	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PRKCA—melanoma	5.79e-05	0.000145	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—ERCC2—melanoma	5.74e-05	0.000144	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTK2B—melanoma	5.73e-05	0.000143	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HIF1A—melanoma	5.7e-05	0.000143	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PPARG—melanoma	5.68e-05	0.000142	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GAB2—melanoma	5.57e-05	0.000139	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GNA11—melanoma	5.57e-05	0.000139	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FLT1—melanoma	5.55e-05	0.000139	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ABCB1—melanoma	5.46e-05	0.000137	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KDR—melanoma	5.45e-05	0.000136	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FN1—melanoma	5.25e-05	0.000131	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HDAC2—melanoma	5.24e-05	0.000131	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCR4—melanoma	5.24e-05	0.000131	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FOXO4—melanoma	5.24e-05	0.000131	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—MYC—melanoma	5.18e-05	0.00013	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—GNAQ—melanoma	5.18e-05	0.00013	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NOTCH1—melanoma	5.14e-05	0.000129	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CD80—melanoma	5.03e-05	0.000126	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PRKCA—melanoma	5.03e-05	0.000126	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—APC—melanoma	5.02e-05	0.000126	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CG—melanoma	5.02e-05	0.000126	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KIT—melanoma	5.02e-05	0.000126	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ERCC2—melanoma	4.99e-05	0.000125	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGF—melanoma	4.96e-05	0.000124	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SYK—melanoma	4.87e-05	0.000122	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PLCB4—melanoma	4.86e-05	0.000122	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NGFR—melanoma	4.78e-05	0.00012	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT3—melanoma	4.78e-05	0.00012	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ITGAV—melanoma	4.78e-05	0.00012	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BRAF—melanoma	4.72e-05	0.000118	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—NOTCH1—melanoma	4.64e-05	0.000116	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IGF1—melanoma	4.6e-05	0.000115	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC6A11—melanoma	4.57e-05	0.000114	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIP4K2A—melanoma	4.57e-05	0.000114	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MTAP—melanoma	4.45e-05	0.000111	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAP2K1—melanoma	4.44e-05	0.000111	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SOCS1—melanoma	4.43e-05	0.000111	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CD—melanoma	4.42e-05	0.000111	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—S100B—melanoma	4.41e-05	0.000111	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPARG—melanoma	4.38e-05	0.00011	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MAPK3—melanoma	4.37e-05	0.000109	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—MYC—melanoma	4.25e-05	0.000106	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—FGF2—melanoma	4.23e-05	0.000106	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB4—melanoma	4.22e-05	0.000106	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN2B—melanoma	4.19e-05	0.000105	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.13e-05	0.000103	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CD86—melanoma	4.05e-05	0.000101	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EDN1—melanoma	4.02e-05	0.000101	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—LUM—melanoma	3.96e-05	9.92e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PHGDH—melanoma	3.96e-05	9.92e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MDM2—melanoma	3.96e-05	9.9e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CG—melanoma	3.94e-05	9.86e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF1—melanoma	3.93e-05	9.83e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CSF2—melanoma	3.93e-05	9.83e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—ERBB2—melanoma	3.9e-05	9.76e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPSE—melanoma	3.89e-05	9.73e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CB—melanoma	3.85e-05	9.63e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—E2F1—melanoma	3.84e-05	9.61e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CUBN—melanoma	3.82e-05	9.55e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PDGFRA—melanoma	3.8e-05	9.52e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPARG—melanoma	3.8e-05	9.51e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ITGB3—melanoma	3.76e-05	9.42e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PRKCA—melanoma	3.76e-05	9.42e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CXCL8—melanoma	3.7e-05	9.26e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SPP1—melanoma	3.69e-05	9.24e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SDHD—melanoma	3.69e-05	9.22e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CSPG4—melanoma	3.69e-05	9.22e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—BSG—melanoma	3.69e-05	9.22e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAP2K2—melanoma	3.68e-05	9.21e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1B—melanoma	3.61e-05	9.04e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GPAM—melanoma	3.57e-05	8.93e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CASP3—melanoma	3.54e-05	8.86e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL2—melanoma	3.53e-05	8.85e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TERT—melanoma	3.5e-05	8.76e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—RAC1—melanoma	3.49e-05	8.73e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CD—melanoma	3.46e-05	8.66e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—melanoma	3.45e-05	8.62e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—ALB—melanoma	3.42e-05	8.55e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CTNNB1—melanoma	3.41e-05	8.54e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HIF1A—melanoma	3.35e-05	8.37e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MMP9—melanoma	3.35e-05	8.37e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDKN1A—melanoma	3.33e-05	8.34e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MAPK3—melanoma	3.33e-05	8.33e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—melanoma	3.33e-05	8.32e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NFKB1—melanoma	3.31e-05	8.28e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MYC—melanoma	3.24e-05	8.11e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KDR—melanoma	3.2e-05	8.01e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FN1—melanoma	3.08e-05	7.71e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PLA2G6—melanoma	3.03e-05	7.6e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CB—melanoma	3.02e-05	7.55e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NOTCH1—melanoma	3.01e-05	7.54e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—VEGFA—melanoma	3e-05	7.52e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—melanoma	2.99e-05	7.48e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—STAT3—melanoma	2.97e-05	7.44e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—melanoma	2.97e-05	7.43e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CD80—melanoma	2.95e-05	7.39e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—APC—melanoma	2.95e-05	7.38e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CG—melanoma	2.95e-05	7.38e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KIT—melanoma	2.95e-05	7.38e-05	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—melanoma	2.95e-05	7.38e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGF—melanoma	2.91e-05	7.29e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK3—melanoma	2.84e-05	7.11e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BRAF—melanoma	2.77e-05	6.94e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MYC—melanoma	2.76e-05	6.92e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—VCAN—melanoma	2.73e-05	6.82e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MAPK1—melanoma	2.7e-05	6.77e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—EGFR—melanoma	2.7e-05	6.77e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IGF1—melanoma	2.7e-05	6.76e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAP2K1—melanoma	2.61e-05	6.53e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—melanoma	2.61e-05	6.53e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CD—melanoma	2.59e-05	6.49e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MAPK3—melanoma	2.56e-05	6.42e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—melanoma	2.55e-05	6.39e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MYC—melanoma	2.49e-05	6.24e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—FGF2—melanoma	2.48e-05	6.21e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PIK3CA—melanoma	2.35e-05	5.87e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MDM2—melanoma	2.32e-05	5.81e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP17A1—melanoma	2.3e-05	5.76e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—ERBB2—melanoma	2.29e-05	5.73e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—melanoma	2.27e-05	5.68e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CB—melanoma	2.26e-05	5.65e-05	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—melanoma	2.25e-05	5.62e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GNA11—melanoma	2.17e-05	5.44e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CXCL8—melanoma	2.17e-05	5.43e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—melanoma	2.17e-05	5.43e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—FASN—melanoma	2.13e-05	5.32e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1B—melanoma	2.12e-05	5.31e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC5A5—melanoma	2.09e-05	5.23e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CASP3—melanoma	2.08e-05	5.2e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—IL6—melanoma	2.08e-05	5.2e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL2—melanoma	2.07e-05	5.19e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—melanoma	2.02e-05	5.06e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—GNAQ—melanoma	2.02e-05	5.05e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CD44—melanoma	2.02e-05	5.05e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CTNNB1—melanoma	2e-05	5.01e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MMP9—melanoma	1.96e-05	4.91e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDKN1A—melanoma	1.96e-05	4.9e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—melanoma	1.95e-05	4.89e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NFKB1—melanoma	1.94e-05	4.86e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CYP1B1—melanoma	1.94e-05	4.85e-05	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—melanoma	1.92e-05	4.8e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PIK3CA—melanoma	1.84e-05	4.6e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—VEGFA—melanoma	1.76e-05	4.41e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—STAT3—melanoma	1.75e-05	4.37e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—melanoma	1.74e-05	4.36e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—melanoma	1.73e-05	4.33e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK3—melanoma	1.67e-05	4.17e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MYC—melanoma	1.62e-05	4.06e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ABCB1—melanoma	1.59e-05	3.99e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MAPK1—melanoma	1.59e-05	3.97e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—EGFR—melanoma	1.59e-05	3.97e-05	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—melanoma	1.5e-05	3.76e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—melanoma	1.5e-05	3.75e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PRKCA—melanoma	1.47e-05	3.67e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ERCC2—melanoma	1.46e-05	3.64e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PIK3CA—melanoma	1.38e-05	3.45e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—melanoma	1.33e-05	3.33e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—melanoma	1.27e-05	3.19e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—IL6—melanoma	1.22e-05	3.05e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CG—melanoma	1.15e-05	2.88e-05	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—melanoma	1.12e-05	2.82e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARG—melanoma	1.11e-05	2.78e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CD—melanoma	1.01e-05	2.53e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—ALB—melanoma	9.97e-06	2.5e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CB—melanoma	8.81e-06	2.2e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—melanoma	8.72e-06	2.18e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—melanoma	7.61e-06	1.9e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PIK3CA—melanoma	5.37e-06	1.34e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—melanoma	4.39e-06	1.1e-05	CbGpPWpGaD
